Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 2175-2177

  Snanoudj, Renaud ^a   Mamzer Bruneel, Marie France ^a   Hermine, Olivier ^a   Grünfeld, Jean Pierre ^a   Chauveau, Dominique ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Acute renal failure; AL amyloidosis; Autologous stem cell transplantation; Nephrotic syndrome

Indexed keywords

ACENOCOUMAROL; ALBUMIN; ANTIBIOTIC AGENT; LISINOPRIL; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE KIDNEY FAILURE; ADULT; AMYLOIDOSIS; ANURIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LEG EDEMA; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NEPHROTIC SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SEPTIC SHOCK; STEM CELL MOBILIZATION;

AMYLOIDOSIS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MELPHALAN; MIDDLE AGED; NEPHROTIC SYNDROME; RECOVERY OF FUNCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0141506995     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg326     Document Type: Article

References (10)

1. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207
2. Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290-298
3. Gertz MA, Kyle RA, O'Fallon WM. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med 1992; 152: 2245-2250
4. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282
5. Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963-969
6. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-3670
7. Dember LM, Sanchorawala V, Seldin DC et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746-753
8. Zeier M, Perz J, Linke R et al. Persistence of glomerular amyloid after autologous blood stem cell transplantation in AL-amyloidosis despite remission of nephrotic syndrome [abstract]. J Am Soc Nephrol 2002; 13
9. Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med 1982; 142: 1445-1447
10. Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial [abstract]. Blood 2001; 98: 815